MedTrace Logo

International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response

NCT05593770 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-05-02

Study results available
· View outcomes & findings →

Summary

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response improves clinical outcomes among patients with COVID-19.

Conditions

  • COVID-19
  • SARS-CoV2 Infection
  • Coronavirus Infection

Interventions

DRUG

Fostamatinib

Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.

DRUG

Placebo

Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses.

Sponsors & Collaborators

  • NEAT ID Foundation

    lead OTHER

Principal Investigators

  • Anton Pozniak, Prof · NEAT ID

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-27
Primary Completion
2023-12-14
Completion
2023-12-14
FDA Drug
Yes

Countries

  • Brazil
  • Germany
  • Italy
  • South Africa
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05593770 on ClinicalTrials.gov